Clauw DJ, Chrousos GP Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997 May-Jun;4(3):134-53. Review.
Clauw DJ Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician. 1995 Sep 1;52(3):843-51, 853-4. Review. Erratum in: Am Fam Physician 1996 Nov 1;54(6):1896, 1901-2.
Compas BE, Haaga DA, Keefe FJ, Leitenberg H, Williams DA Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. J Consult Clin Psychol. 1998 Feb;66(1):89-112. Review.
Deale A, Chalder T, Marks I, Wessely S Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry. 1997 Mar;154(3):408-14.
Emmelkamp PM, van Oppen P Cognitive interventions in behavioral medicine. Psychother Psychosom. 1993;59(3-4):116-30. Review.
Godfrey RG A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med. 1996 May 27;156(10):1047-52. Review.
Lachin JM Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113.
Lacker JM, Carosella AM, Feuerstein M Pain expectancies, pain, and functional self-efficacy expectancies as determinants of disability in patients with chronic low back disorders. J Consult Clin Psychol. 1996 Feb;64(1):212-20.
Lipchik GL, Milles K, Covington EC The effects of multidisciplinary pain management treatment on locus of control and pain beliefs in chronic non-terminal pain. Clin J Pain. 1993 Mar;9(1):49-57.
Melzack R The short-form McGill Pain Questionnaire. Pain. 1987 Aug;30(2):191-7.
Muehrer P Research on adherence, behavior change, and mental health: a workshop overview. Health Psychol. 2000 May;19(3):304-7.
Nguyen TD, Attkisson CC, Stegner BL Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire. Eval Program Plann. 1983;6(3-4):299-313.
Nielson WR, Walker C, McCain GA Cognitive behavioral treatment of fibromyalgia syndrome: preliminary findings. J Rheumatol. 1992 Jan;19(1):98-103.
Rosenstiel AK, Keefe FJ The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983 Sep;17(1):33-44.
Walters SJ, Brazier JE What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003 Apr 11;1:4.
Ware JE Jr, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. JAMA. 1996 Oct 2;276(13):1039-47.
White KP, Nielson WR Cognitive behavioral treatment of fibromyalgia syndrome: a followup assessment. J Rheumatol. 1995 Apr;22(4):717-21.
Yunus MB Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol. 1992 Jun;19(6):846-50.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.